Entities / Company
Leerink partners.
U.S. investment bank
- Reports this week
- 10
- Active events
- 6
- Connections
- 212
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Kazia Therapeutics Limited is seeking joint bookrunning management and co-management for a proposed offering, with Leerink partners and Needham & Company involved.Well supported17 reports1 development inside
-
Leerink Partners is acting as a placement agent for First Tracks Biotherapeutics.Some support1 report
-
Citigroup raised its rating on Innate Pharma stock, which trades on the Nasdaq exchange. Leerink Partners also upgraded the rating. MarketBeat aggregates the rating data.Some support1 report1 development inside
-
Leerink Partners assumed coverage on Equillium shares, with data reported by MarketBeat from Nasdaq listed stocks.Some support1 report
-
Leerink Partners upgraded Gossamer Bio stock rating on September 26, 2026.Some support2 reports
-
Leerink Partners assumed coverage on Nektar Therapeutics shares on October 13, 2026.Some support2 reports
Earlier this month
-
Royal Bank of Canada downgraded Caribou Biosciences stock, and Leerink partners updated its ratings on October 9, 2026.Some support2 reports
-
Leerink Partners, Truist Financial, HSBC, and Cantor Fitzgerald raised target prices on various stocks on October 9, 2026.Some support1 report
-
Moderna's stock performance is tracked on Nasdaq while Leerink Partners leads a Nasdaq IPO, amid oil price volatility and AI regulation tests.Some support1 report
-
Citigroup reissued a market outperform rating and Leerink Partners began coverage on Rapport Therapeutics.Some support1 report
-
Leerink Partners is a joint bookrunning manager for an offering by Retension Pharmaceuticals, Inc., with the prospectus available from Boston, MA.Some support2 reports
-
Leerink Partners, Cantor Fitzgerald, and Barclays acted as placement agents for Atrium on October 8, 2026.Some support1 report
-
Leerink Partners increased its price target and Morgan Stanley reiterated an overweight rating for REGENXBIO Inc.Some support1 report
-
Leerink Partners started coverage on Nautilus Biotechnology on October 6, 2026.Some support1 report
-
Leerink Partners is acting as a joint book-running manager for an offering by Spyre Therapeutics, Inc.Some support1 report
-
Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.Some support6 reports
-
A filing required by the SEC concerning McKesson Corporation shares, accompanied by analyst commentary.Well supported7 reports
-
Leerink Partners provided coverage and price targets for Freenome on September 26, 2026.Some support1 report
-
Needham & Company issued a buy rating, and Leerink Partners began coverage of Collegium Pharmaceutical, Inc. on September 23, 2026.Some support2 reports
-
Leerink partners issued an 'outperform' rating on Teva stock, while an insider sold shares of the company.Some support3 reports
-
Analyst firm Leerink partners raised the price target for Roivant based on share count forecast on August 13, 2025.Well supported4 reports1 development inside
-
An analyst firm has provided price target recommendations for Universal Health Services.Some support1 report
One to three months ago
-
Leerink Partners started coverage on ANI Pharmaceuticals shares.Some support2 reports
-
Analyst firm upgraded price objective on 10X Genomics stock.Some support1 report
-
Leerink raised its price target for UnitedHealth Group stock.Some support2 reports
-
Leerink partners, TD Cowen, and William Blair initiated coverage and set ratings for Kailera Therapeutics.Some support1 report
-
Truist Financial and Leerink Partners raised price objectives for Eli Lilly and Company stock.Some support1 report
-
TD Cowen raised price targets for GoodRx stock.Some support1 report
-
Financial analysts reviewed Biohaven's strategic asset sales and corporate strategy following its acquisition by Pfizer.Some support1 report
-
Scribe Therapeutics completed its IPO, led by Leerink Partners, with major backing from Eli Lilly and Andreessen Horowitz.Some support2 reports
-
Leerink partners provided research reports on AirSculpt Technologies on August 17, 2026.Some support1 report
-
Leerink Partners cut price target on Stryker Corporation, and Norges Bank bought a new position in Stryker shares.Some support1 report
-
Cantor Fitzgerald and Leerink partners issued rating changes for Replimune Group, Inc. on July 13, 2026.Some support2 reports
-
Cantor Fitzgerald and Leerink Partners initiated analyst coverage on Avidity Biosciences on August 10, 2026.Some support3 reports
-
MarketBeat is providing consensus rating for Alamar Biosciences, and Leerink Partners and Bank of America have initiated coverage on the company.Some support1 report
-
Analyst coverage is influencing stock price targets for companies including Bank of America, Eli Lilly and Company, Leerink partners, and Cantor Fitzgerald.Some support10 reports6 developments inside
-
Halozyme's stock performance was mentioned in proximity to Leerink Partners on August 7, 2026.Some support1 report
-
LB Pharmaceuticals Inc is seeking institutional investment for a private placement, utilizing Leerink Partners as the placement agent, with BB Biotech as a key entity.Some support1 report1 development inside
-
Leerink partners began its role as the lead book-running manager for an offering on behalf of BlossomHill Therapeutics, Inc. on August 1, 2026.Some support1 report
-
Summit seeks FDA approval for its drug, which was presented at the ASCO meeting. The company is developing ivonescimab with Akeso.Well supported6 reports
-
Analyst downgrades are affecting Leerink partners' stock price, which is listed on the Nasdaq stock exchange.Some support2 reports
-
Leerink partners adjusted its rating and target price for Medtronic plc on July 31, 2026.Some support1 report
-
Scribe Therapeutics is based in Alameda, California, while Leerink Partners maintains an office in Boston, MA. The article also notes Goldman Sachs has an office in New York.Some support1 report
-
Leerink Partners raised price target for Thermo Fisher Scientific Inc. (TMO) on July 23, 2026.Some support2 reports
-
SpaceX's IPO was expected to top US deals, with Jack Bannister identified as senior managing director at Leerink Partners.Some support1 report
Gone quiet
No new reports in 90+ days-
Leerink partners set a $152.00 target price on Encompass Health shares.Some support1 report
-
Veradermics, Incorporated is facing market challenges in the US, with analyst reports affecting its stock price.Some support3 reports
-
Arcus Biosciences' stock rating and price were influenced by analyst reports, and the company filed with the SEC regarding institutional purchases.Well supported7 reports
-
The Tennessee Department of Treasury bought a new position in stock, while Citigroup reaffirmed its 'outperform' rating and Leerink Partners set a $43.00 price objective.Some support1 report
-
The FDA granted premarket approval for the LungFX device for use with United Therapeutics, while Leerink partners maintained an Outperform rating on the company's shares.Some support2 reports
-
Berenberg Bank and Leerink Partners raised price targets for Eli Lilly and Company on July 8, 2026.Some support5 reports
-
Leerink partners provided research notes on the stock of CorMedix Inc. on July 2, 2026.Some support2 reports
-
Leerink partners evaluates Abivax drug safety data on July 1, 2026.Some support1 report
-
Morgan Stanley and Leerink partners provided buy ratings and target prices for AgomAb Therapeutics on June 29, 2026.Some support3 reports
-
Leerink partners maintained a Buy rating on Ardelyx on June 25, 2025.Speculative1 report1 development inside
-
Analyst firm reaffirmed rating on Ardelyx stock, while an insider sold company shares.Some support1 report
-
Cantor Fitzgerald and Leerink partners are acting as joint bookrunning managers for an offering involving a Swiss company, requiring an SEC filing.Some support2 reports
-
An analyst firm provided target price updates for Oruka Therapeutics, Inc. on June 6, 2026.Some support5 reports
-
Leerink partners and Truist Financial issued research reports, including buy ratings and price objective lifts, regarding Absci Corporation's stock.Some support4 reports
-
MarketBeat aggregates analyst ratings and Benzinga reports on ARS Pharmaceuticals, which saw Leerink Partners cut its price target to $24.00.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Leerink partners this week
News at the entities that move Leerink partners most-
BrightSpring Health Services OperationalBrightSpring Health Services filed a disclosure with the SEC on August 17, 2026.Moves Leerink partners
-
company TransactionalGermano was appointed to the Board of Directors of Eloxx Pharmaceuticals.Moves Leerink partners
-
Nasdaq OperationalBroadcom and Applied Materials are semiconductor industry players both listed on the Nasdaq exchange.Moves Leerink partners
-
Needham & Company OperationalTD Cowen and Needham & Company boosted the price target and gave a 'buy' rating for Ultra Clean.Moves Leerink partners
-
Intuitive Surgical Mentioned togetherCitigroup and Baird lowered their stock targets for Intuitive Surgical on October 19, 2026.Moves Leerink partners
-
Cantor Fitzgerald OperationalCantor Fitzgerald and Jefferies Financial Group downgraded EyePoint Pharmaceuticals' stock rating from overweight/buy to neutral/hold on October 19, 2026.Moves Leerink partners
Connections
The 40 strongest of 212, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
BrightSpring Health Services Operational
Leerink Partners provides financial analysis and acts as a bookrunner for BrightSpring Health Services' offerings.
-
Faisal Khurshid Structural
Faisal Khurshid is employed as an analyst at Leerink Partners.
-
Nasdaq Operational
Leerink Partners actively facilitates and provides coverage for companies listing or trading on the Nasdaq exchange.
-
company Transactional
Leerink partners and the company are jointly appointed as bookrunning managers for a financial offering.
-
Jack Bannister Structural
Jack Bannister serves as a senior managing director at Leerink Partners.
-
Aquestive (United States) Transactional
Leerink partners jointly managed a stock offering for Aquestive.
-
Bristol-Myers Squibb Operational
Leerink Partners provides market commentary and rating changes regarding companies in the pharmaceutical sector.
-
Incyte Transactional
Leerink partners increased its price objective regarding Incyte.
Show all 40 connections
-
Regeneron Pharmaceuticals Operational
Leerink Partners provides financial analysis and rating updates for Regeneron Pharmaceuticals.
-
Scribe Therapeutics Operational
Leerink Partners actively influenced Scribe Therapeutics by leading its IPO and providing market ratings.
-
Caribou Biosciences Mentioned together
Leerink partners updated Caribou Biosciences ratings, lowering its share performance outlook.
-
Needham & Company Operational
Both Needham & Company and Leerink partners are actively involved in managing a stock offering.
-
Roivant Sciences (United States) Mentioned together
Leerink partners provides financial analysis and price targets for Roivant Sciences.
-
Merck KGaA Mentioned together
Leerink partners provides financial coverage, consistently raising price targets and ratings for Merck KGaA.
-
Medtronic plc Mentioned together
Leerink partners provides market research and analysis on Medtronic plc's stock performance.
-
UnitedHealth Group Mentioned together
Leerink partners provides financial analysis, including price targets and ratings, for UnitedHealth Group stock.
-
Nanobiotix Mentioned together
Leerink partners provides analyst ratings and price targets for Nanobiotix stock.
-
GoodRx Mentioned together
Leerink Partners provides financial research and price targets for GoodRx stock.
-
Arrowhead Pharmaceuticals Mentioned together
Leerink partners issued a price target and rating for Arrowhead Pharmaceuticals.
-
Acadia Healthcare Mentioned together
Leerink Partners provides financial research and price objective recommendations for Acadia Healthcare.
-
Encompass Health Mentioned together
Leerink Partners provides financial analysis and sets price targets for Encompass Health.
-
Stryker Corporation Mentioned together
Leerink partners provides financial research and analyst coverage regarding Stryker Corporation's stock.
-
Intuitive Surgical Mentioned together
Leerink Partners provides financial analysis and bullish ratings on Intuitive Surgical.
-
Halozyme Therapeutics Mentioned together
Leerink Partners functions as an analyst firm, providing market research reports and assessments on Halozyme Therapeutics.
-
Illumina Mentioned together
Leerink partners provides financial research reports and price targets regarding Illumina.
-
Insmed Transactional
Leerink Partners acted as a joint book-running manager for Insmed during a financial offering.
-
Doximity Operational
Leerink Partners actively influenced Doximity's market perception by decreasing its target price.
-
United Therapeutics Mentioned together
Leerink Partners provides investment ratings and coverage on United Therapeutics stock.
-
Teva Pharmaceutical Industries Ltd. Mentioned together
Leerink Partners provides financial coverage and ratings on Teva Pharmaceutical Industries Ltd. stock.
-
Cantor Fitzgerald Operational
The two companies actively collaborate as joint bookrunning managers in financial transactions.
-
Edwards Lifesciences Operational
Leerink Partners provides market analysis, including rating changes and price targets, for Edwards Lifesciences.
-
Guardant Health Transactional
Leerink partners issued a price objective rating on Guardant Health.
-
Kymera Therapeutics Transactional
Leerink Partners served as a joint book-running manager for Kymera Therapeutics.
-
MannKind Corporation Mentioned together
Leerink Partners provides financial ratings and price targets for MannKind Corporation.
-
Arcus Biosciences Operational
Leerink partners' analyst reports and target prices are observed to influence Arcus Biosciences' stock rating and price.
-
PROCEPT BioRobotics Mentioned together
Analysts from Leerink partners issue ratings and commentary that affect PROCEPT BioRobotics' valuation.
-
Universal Health Services Mentioned together
Market analysts are providing price target recommendations for both companies.
-
Amneal Pharmaceuticals, Inc. Mentioned together
The relationship is based on shared market research coverage and analyst ratings.
-
Neurocrine Biosciences Mentioned together
Leerink Partners has provided analyst coverage, including raising the target price, for Neurocrine Biosciences.
-
Bruker Mentioned together
Leerink Partners issued a price objective recommendation regarding Bruker.
History
Events by the month they beganOctober 2026
12 events- Leerink Partners is acting as a placement agent for First Tracks Biotherapeutics.
- Leerink Partners assumed coverage on Equillium shares, with data reported by MarketBeat from Nasdaq listed stocks.
- Leerink Partners assumed coverage on Nektar Therapeutics shares on October 13, 2026.
- Royal Bank of Canada downgraded Caribou Biosciences stock, and Leerink partners updated its ratings on October 9, 2026.
- Leerink Partners, Truist Financial, HSBC, and Cantor Fitzgerald raised target prices on various stocks on October 9, 2026.
- Moderna's stock performance is tracked on Nasdaq while Leerink Partners leads a Nasdaq IPO, amid oil price volatility and AI regulation tests.
- Citigroup reissued a market outperform rating and Leerink Partners began coverage on Rapport Therapeutics.
- Leerink Partners is a joint bookrunning manager for an offering by Retension Pharmaceuticals, Inc., with the prospectus available from Boston, MA.
- Leerink Partners, Cantor Fitzgerald, and Barclays acted as placement agents for Atrium on October 8, 2026.
- Leerink Partners increased its price target and Morgan Stanley reiterated an overweight rating for REGENXBIO Inc.
- Leerink Partners started coverage on Nautilus Biotechnology on October 6, 2026.
- Leerink Partners is acting as a joint book-running manager for an offering by Spyre Therapeutics, Inc.
September 2026
9 events- Leerink Partners upgraded Gossamer Bio stock rating on September 26, 2026.
- Leerink Partners provided coverage and price targets for Freenome on September 26, 2026.
- Needham & Company issued a buy rating, and Leerink Partners began coverage of Collegium Pharmaceutical, Inc. on September 23, 2026.
- Leerink partners issued an 'outperform' rating on Teva stock, while an insider sold shares of the company.
- An analyst firm has provided price target recommendations for Universal Health Services.
- Leerink Partners started coverage on ANI Pharmaceuticals shares.
- Analyst firm upgraded price objective on 10X Genomics stock.
- Leerink partners, TD Cowen, and William Blair initiated coverage and set ratings for Kailera Therapeutics.
- Truist Financial and Leerink Partners raised price objectives for Eli Lilly and Company stock.
August 2026
11 events- Kazia Therapeutics Limited is seeking joint bookrunning management and co-management for a proposed offering, with Leerink partners and Needham & Company involved.
- Citigroup raised its rating on Innate Pharma stock, which trades on the Nasdaq exchange. Leerink Partners also upgraded the rating. MarketBeat aggregates the rating data.
- TD Cowen raised price targets for GoodRx stock.
- Financial analysts reviewed Biohaven's strategic asset sales and corporate strategy following its acquisition by Pfizer.
- Leerink partners provided research reports on AirSculpt Technologies on August 17, 2026.
- Leerink Partners cut price target on Stryker Corporation, and Norges Bank bought a new position in Stryker shares.
- Cantor Fitzgerald and Leerink Partners initiated analyst coverage on Avidity Biosciences on August 10, 2026.
- MarketBeat is providing consensus rating for Alamar Biosciences, and Leerink Partners and Bank of America have initiated coverage on the company.
- Halozyme's stock performance was mentioned in proximity to Leerink Partners on August 7, 2026.
- Leerink partners began its role as the lead book-running manager for an offering on behalf of BlossomHill Therapeutics, Inc. on August 1, 2026.
- Analyst downgrades are affecting Leerink partners' stock price, which is listed on the Nasdaq stock exchange.
Show 2 earlier months
July 2026
16 events- Scribe Therapeutics completed its IPO, led by Leerink Partners, with major backing from Eli Lilly and Andreessen Horowitz.
- Cantor Fitzgerald and Leerink partners issued rating changes for Replimune Group, Inc. on July 13, 2026.
- Analyst coverage is influencing stock price targets for companies including Bank of America, Eli Lilly and Company, Leerink partners, and Cantor Fitzgerald.
- LB Pharmaceuticals Inc is seeking institutional investment for a private placement, utilizing Leerink Partners as the placement agent, with BB Biotech as a key entity.
- Leerink partners adjusted its rating and target price for Medtronic plc on July 31, 2026.
- Scribe Therapeutics is based in Alameda, California, while Leerink Partners maintains an office in Boston, MA. The article also notes Goldman Sachs has an office in New York.
- Leerink Partners raised price target for Thermo Fisher Scientific Inc. (TMO) on July 23, 2026.
- SpaceX's IPO was expected to top US deals, with Jack Bannister identified as senior managing director at Leerink Partners.
- Leerink partners set a $152.00 target price on Encompass Health shares.
- Veradermics, Incorporated is facing market challenges in the US, with analyst reports affecting its stock price.
- Arcus Biosciences' stock rating and price were influenced by analyst reports, and the company filed with the SEC regarding institutional purchases.
- The Tennessee Department of Treasury bought a new position in stock, while Citigroup reaffirmed its 'outperform' rating and Leerink Partners set a $43.00 price objective.
- The FDA granted premarket approval for the LungFX device for use with United Therapeutics, while Leerink partners maintained an Outperform rating on the company's shares.
- Berenberg Bank and Leerink Partners raised price targets for Eli Lilly and Company on July 8, 2026.
- Leerink partners provided research notes on the stock of CorMedix Inc. on July 2, 2026.
- Leerink partners evaluates Abivax drug safety data on July 1, 2026.
June 2026
12 events- Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.
- A filing required by the SEC concerning McKesson Corporation shares, accompanied by analyst commentary.
- Analyst firm Leerink partners raised the price target for Roivant based on share count forecast on August 13, 2025.
- Leerink raised its price target for UnitedHealth Group stock.
- Summit seeks FDA approval for its drug, which was presented at the ASCO meeting. The company is developing ivonescimab with Akeso.
- Morgan Stanley and Leerink partners provided buy ratings and target prices for AgomAb Therapeutics on June 29, 2026.
- Leerink partners maintained a Buy rating on Ardelyx on June 25, 2025.
- Analyst firm reaffirmed rating on Ardelyx stock, while an insider sold company shares.
- Cantor Fitzgerald and Leerink partners are acting as joint bookrunning managers for an offering involving a Swiss company, requiring an SEC filing.
- An analyst firm provided target price updates for Oruka Therapeutics, Inc. on June 6, 2026.
- Leerink partners and Truist Financial issued research reports, including buy ratings and price objective lifts, regarding Absci Corporation's stock.
- MarketBeat aggregates analyst ratings and Benzinga reports on ARS Pharmaceuticals, which saw Leerink Partners cut its price target to $24.00.